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Abstract
The role of radiologic imaging in the investigation of irritable bowel syndrome
(IBS) remains a subject of debate and there is some evidence, from recent studies
of utilization of imaging in IBS, which focused on associated costs and radiation
exposure, that imaging is being used relatively widely in these patients. This
review aims to  assess  current  best  evidence  to  accurately  define  the  role  of
radiologic imaging in IBS patients. Primary and secondary literature searches
were performed. Evidence suggests that the lack of “red flag” or alarm features in
IBS patients should reassure the clinician that the diagnosis of IBS is correct and
United States and United Kingdom guidelines recommend no radiologic imaging
for IBS patients if alarm features are not present. In patients presenting with IBS
symptoms and alarm features,  radiologic testing may be used to exclude an
alternative diagnosis and the imaging modality should be chosen based on the
most likely alternative diagnosis.
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Core tip: Radiologic imaging in irritable bowel syndrome (IBS) remains contentious
and the evidence guiding its use is limited. Recent studies indicate that imaging is being
widely used in these patients. This review assesses current best evidence for the role of
imaging  in  IBS.  Primary  and  secondary  literature  searches  were  performed.  The
cornerstone of diagnosis remains the Rome criteria. Lack of “red flag” features in IBS
patients should strengthen diagnosis of IBS and obviate the need for radiologic imaging.
If red flag features are present, appropriate imaging may be used to exclude a suspected
alternative diagnosis.
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INTRODUCTION
Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder (FGID)
that is broadly characterized by recurrent abdominal pain and alterations in stool
consistency or form[1]. Multinational expert groups in FGIDs have devised the Rome
criteria, most recently Rome IV criteria, as a symptom-based diagnostic standard to
diagnose  IBS.  Despite  this,  as  IBS  is  associated  with  loss  of  work  days  and
productivity and negatively impacts quality of life, it often remains a diagnosis of
exclusion  after  invasive  investigations  are  performed  to  rule  out  other  specific
pathology. Interestingly, a comparison of an exclusion approach to diagnosis of IBS,
using investigations such as sigmoidoscopy, and a positive diagnostic approach using
the Rome criteria, showed little differences in terms of patients’ health-related quality
of life in one Danish study of over 300 patients[2]. The positive diagnostic approach
based on Rome criteria,  was however,  cheaper when compared to the exclusion
approach. This study supports current guideline recommendations and suggests an
unnecessary reliance on alternative diagnostic investigations.
Epidemiology
The worldwide prevalence of IBS is estimated to be 7%-10% with wide geographic
variability [3].  In  the  United  States  the  prevalence  of  IBS  is  estimated  to  be
approximately 10% to 15%[4] and one large European prospective, population-based
cohort study estimated prevalence of 15.4%[5]. IBS is less common in people older than
50 compared with those younger than 50 (OR 0.75)[6] and is more common in women
compared with  men (OR 1.67)[7].  IBS  may be  associated with  a  number  of  other
disorders including fibromyalgia, depression, chronic fatigue syndrome, non-cardiac
chest pain and anxiety[4]. There is conflicting evidence regarding IBS prevalence and
socioeconomic status[6,8,9] and this relationship remains unproven.
Pathophysiology
That the diagnosis and management of IBS relies on clinical symptoms highlights that
the pathophysiology remains incompletely understood. Initial research in the early
20th  century  utilizing direct  visualization of  the  gastric  mucosa  in  patients  with
gastrocutaneous  fistulae  provided  the  first  scientific  evidence  that  the  gut  is
physiologically responsive to stressful emotional and environmental stimuli. Later
studies  showed  that  patients  with  IBS-type  symptoms  had  an  enhanced
gastrointestinal  motor  response  to  various  stimuli  such  as  fatty  meals,  peptide
hormones  and  psychological  stressors  and  increased  motility  was  sometimes
associated with pain[10]. Recent advances in knowledge have, however, facilitated an
increased understanding of the underlying disease processes, but it remains likely
that there are multiple etiological factors involved. Those currently implicated in IBS
symptom  presentation  include  altered  gastrointestinal  motility,  visceral
hypersensitivity, post-infectious gastroenteritis, intestinal inflammation, altered gut
microbiota, food sensitivity and interactions of the brain-gut axis[11].  IBS linked to
brain-gut interactions is suggested by the association of IBS with anxiety, depression
and other psychiatric conditions[1]. Furthermore, it is recognized that psychological
stress exacerbates and exaggerates the symptoms of IBS and associated psychological
and psychiatric  co-morbidity  negatively  influence  the  patient  experience  of  the
condition[12]. Persistent post infectious gastroenteritis IBS-type symptoms are common
in up to 20% of cases[1],  and this  is  linked to an intestinal  inflammatory etiology
indicating an alternate pathogenesis to brain-gut interactions[13]. Further etiological
factors for IBS development include alterations in gut microbiota and associated
predisposing influences on both the microbiome and IBS symptoms including host
genetics, stress, diet, antibiotic use and early life experiences[14]. Gut microbiota and
their metabolites have notable influences on recognised IBS associations including the
brain-gut axis, visceral hypersensitivity, gastrointestinal motility, intestinal barrier
function  and  immune  regulation[14].  Though  causation  is  not  established,  the
expanding science  of  the  human gut  microbiome and microbe-host  interactions
suggest gut microbial alterations play a key role in IBS pathophysiology[14].  These
various pathophysiological factors may co-exist in the same patient, adding to the
heterogeneity and complexity of understanding IBS and may, in part, explain the
varying response to current symptom based treatments[15].
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Diagnosis
The Rome criteria are criteria that were devised by expert consensus for the diagnosis
of FGIDs; these criteria define multiple different FGID including IBS. The most recent
iteration of these criteria is the Rome IV, released in 2016. The diagnostic criteria for
IBS by the Rome IV criteria are as follows[16]: Recurrent abdominal pain, on average, at
least one day per week in the last 3 mo associated with two or more of the following:
Pain related to defecation; Associated with a change in frequency of stool; Associated
with a change in form (appearance) of stool. The criteria should be fulfilled for the last
3 mo with symptom onset at least 6 mo before diagnosis.
By the Rome IV criteria, the IBS subtype is classified based on the predominant
symptom of constipation or diarrhea as follows[16]: IBS with predominant constipation
(IBS-C); IBS with predominant diarrhea (IBS-D); IBS with mixed bowel habits (IBS-M);
IBS unclassified (IBS-U).
This classification is based upon the percentage of different stool types as defined
by the Bristol stool scale. IBS-C is diagnosed if > 25% are stool type 1 and 2 and < 25%
are stool type 6 and 7; IBS-D is diagnosed if < 25% are stool type 1 and 2 and > 25%
are stool type 6 and 7; and IBS-M is diagnosed if > 25% are stool type 1 and 2 and >
25% are stool type 6 and 7. IBS-U is diagnosed if the patient meets diagnostic criteria
for IBS but stool type cannot be accurately categorized into one of the other subtypes.
Assessment for alarm features should be performed in all patients that meet the
diagnostic  criteria  for  IBS[17].  The  aim  of  identifying  alarm  features  is  to  allow
consideration of further investigations in patients with signs/symptoms of other
possible underlying conditions such as colorectal/ovarian cancer and inflammatory
bowel disease. Alarm features include the following[16,18,19]: New onset, or overt, rectal
bleeding or melena; Nocturnal pain or diarrhea; Iron-deficiency anemia; Unexplained
weight loss; Family history of colon cancer, ovarian cancer, celiac disease, IBD; Fever;
Age  of  onset  >  50  years;  Severe  or  progressively  worsening  symptoms;
Abdominal/pelvic/rectal mass or lymphadenopathy; Recent change in bowel habits.
Although the prevalence of alarm features is high in IBS patients[18] the sensitivity of
alarm features in predicting organic disease in patients with typical symptoms of IBS
is low. This may be due to the fact that besides celiac disease, which a large systematic
review demonstrated is four times as prevalent in patients with IBS compared with
the general population[20], the prevalence of underlying organic disease is the same in
patients with IBS as in the general population[3]. However, certain alarm features such
as  weight  loss  and anemia  do  offer  high  specificity  for  organic  disease  and the
American College of Gastroenterology (ACG) state that the absence of alarm features
should reassure the clinician that the diagnosis of IBS is correct[3].
IBS burden of disease
IBS is a disease that is associated with significantly reduced health-related quality of
life  and impaired work productivity[3].  IBS patients  utilize  50% more healthcare
resources than matched controls without IBS and overall direct and indirect annual
healthcare costs in these patients are estimated at $20 billion[3]. This increased cost can
be attributed not only to increased medication use but also increased diagnostic
testing and lost  wages.  In  1995,  Talley et  al[21]  estimated the excess  yearly  direct
healthcare cost of IBS in the United States to be $8 billion and extrapolating from that
study, excess cost of approximately $800 million was estimated for radiology services
in these patients. This highlights the importance of accurately defining the role of
radiologic  imaging  in  the  investigation  of  patients  presenting  with  IBS-type
symptoms in order to rationalize the use of this expensive and, in certain jurisdictions,
limited resource.
As  well  as  increased  costs,  another  concern  regarding  the  over-utilization  of
radiologic diagnostic testing is the radiation exposure imparted as a result of plain
radiography,  nuclear  medicine  and  CT  imaging.  Although  there  is  evidence  of
significant costs associated with radiologic imaging in these patients there is a paucity
of  studies  assessing  radiation  exposure  in  this  patient  group.  Englund  et  al[22]
demonstrated that over a 10-year period in Sweden, 149 IBS patients had a radiation
exposure similar to that of a subgroup of patients with ulcerative colitis. A direct
comparison of radiation exposure in IBS patients with that of the general population
was not performed in this study so it  is  difficult  to draw conclusions from these
results. This result does, however, again demonstrate that radiologic imaging is still
being used frequently in the investigation of patients with IBS.
ROLE OF RADIOLOGIC IMAGING IN IBS
The exact role of abdominal radiologic imaging in IBS remains poorly defined and
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some studies suggest that imaging is being used relatively widely in this patient
population[21,22]. There is a marked paucity of modern scientific studies regarding the
appropriate use of imaging in this patient group[23].
In terms of international guidelines, the ACG state the following in their position
statement  on  IBS[3]  based  on  an  evidence-based  systematic  review[24]:  “Routine
diagnostic testing with complete blood count, serum chemistries, thyroid function
studies, stool for ova and parasites, and abdominal imaging is not recommended in
patients with typical IBS symptoms and no alarm features because of a low likelihood
of uncovering organic disease”.
The ACG do recommend serological testing for celiac disease and colonoscopy in
patients with alarm features and those over the age of 50 to assess for colorectal
cancer. When colonoscopy is performed in patients with IBS-D, the ACG recommend
random biopsies are taken to assess for microscopic colitis.
The United Kingdom National Institute for Health and Care Excellence (NICE)
guidelines address the use of radiologic testing explicitly in their recommendations as
follows[17]: “The following tests are not necessary to confirm diagnosis in people who
meet  the  IBS  diagnostic  criteria:  Ultrasound;  Rigid/flexible  sigmoidoscopy;
Colonoscopy; barium enema; Thyroid function test;  Faecal  ova and parasite test;
Faecal occult blood; Hydrogen breath test”.
In an evidence-based review of the role of abdominal radiologic imaging in IBS by
O’Connor et al[23] in 2012, the authors assessed that the best available evidence that
included seven systematic reviews/guidelines and five primary research articles
focusing on the use of barium enema and/or ultrasound. The authors concluded that
radiologic imaging is not required in patients fulfilling the clinical diagnostic criteria
for IBS if alarm symptoms are not present. The authors also concluded that further
investigation  should  be  considered  in  patients  with  alarm  features  and  the
appropriate modality should be chosen on a case-by-case basis and guided by the
most  likely alternative diagnosis  and the American College of  Radiology (ACR)
Appropriateness  Criteria.  The  lack  of  robust  evidence  and  prospective  studies
regarding the role of abdominal radiologic imaging is noted in this review.
Since this review, several studies have used MRI to investigate IBS patients. These
studies aimed to demonstrate differences in bowel response to food ingestion in IBS
patients relative to healthy volunteers[25,26] and differences between the various IBS
subtypes[27]. These studies suggest various sites of pathology to explain IBS symptoms
but  it  is  difficult  to  draw any firm conclusions  from these  studies  due  to  small
numbers and heterogeneous, and sometimes conflicting, results. No definitive role
has been established for the routine use of MRI in the investigation of IBS and no
studies have been performed to assess the performance of MRI relative to symptom-
based diagnostic criteria.
In  the  setting  of  IBS  patients  that  also  demonstrate  alarm  features,  further
investigations should be guided by the most likely alternative diagnosis; this will
often involve endoscopic assessment of the bowel but radiologic testing has a role in
some  circumstances.  For  example  if  a  patient  presents  with  signs/symptoms
suggestive of colorectal cancer NICE guidelines recommend direct visualization with
colonoscopy/sigmoidoscopy or CT colonography in patients unfit for colonoscopy. In
the  setting  of  a  suspected  ovarian  neoplasm  a  pelvic  ultrasound  is  the  first
investigation  recommended  by  the  ACR.  In  a  patient  with  signs/symptoms
suggestive of inflammatory bowel disease radiologic imaging studies (e.g., CT or MR
enterography) may be used to supplement findings on laboratory and endoscopic
studies in order to establish a diagnosis[28].
CONCLUSION
There  remains  a  paucity  of  robust  evidence  regarding  the  appropriate  use  of
abdominal radiologic imaging in the setting of IBS and no modern prospective studies
exist. Symptom-based diagnostic criteria have a high sensitivity and specificity for
diagnosing IBS. Alarm symptoms are common in IBS patients but demonstrate low
sensitivity for alternative organic pathology if diagnostic criteria for IBS are satisfied.
Weight loss and anemia have a high specificity for underlying organic disease and in
patients  meeting diagnostic  criteria  without alarm features,  clinicians should be
reassured that the diagnosis of IBS is correct.
Based on the current best evidence, the diagnosis of IBS should be based on clinical
findings using expert consensus diagnostic criteria (Rome IV criteria) supplemented
by laboratory testing with no role for abdominal radiologic imaging in most patients.
In patients presenting with IBS symptoms and alarm features, radiologic testing may
be used to investigate for an underlying organic disease and the imaging modality
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should be chosen based on the most  likely alternative diagnosis  (see Table 1 for
practice guideline recommendations).
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Table 1  Practice guideline recommendations
Patients fulfilling the Rome IV diagnostic criteria for IBS and who do not display “red flag” symptoms such as blood in stool, weight loss, recurrent
fevers, anemia, and chronic severe diarrhea and who have no family history of colorectal cancer, inflammatory bowel disease, or celiac sprue do not
require radiologic imaging
Radiologic imaging is required in patients with “red flag” symptoms who fulfill the Rome IV diagnostic criteria for IBS
Consideration of the probable alternative diagnosis and adherence to the relevant American College of Radiology Appropriateness Criteria should direct
the optimal radiologic imaging of the patient with IBS
IBS: Irritable bowel syndrome.
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